Options Lab receives federal funding for COVID-19 prevention trial, ranking 2nd out of 438 in competition
Darrell elected to the Governing Council of the International AIDS Society
As of June 25, 2020, the Options Lab received federal funding for a COVID-19 clinical trial which aims to investigate if a 14 day course of oral Kaletra (lopinavir/ritonavir), which is currently used as one strategy for HIV post-exposure prophylaxis (PEP), is effective as COVID-19 PEP. More information can be found here.
CATIE Interview: Darrell Talks PrEP and nPEP Guidelines
As of June 8, 2020, Darrell has been elected to the Governing Council of the International AIDS Society (IAS). You can read more about this here.
Globe and Mail: Higher-risk groups should get greater access to HIV drugs, new guidelines say
Darrell sat down with the folks at CATIE to discuss PrEP and the publication of Canada’s first PrEP and nPEP Guidelines in CMAJ.
CBC News: Toronto Public Health concerned new anti-HIV drug could contribute to spread of other STIs
Darrell spoke with the Globe and Mail about the PrEP and nPEP guidelines and the importance of educating more providers about PrEP to support scale-up. “Because PrEP is so effective in treating HIV, the goal is that by increasing uptake, we could actually move Canada towards a reduction in the rate of HIV infections every […]
CBC News: Can an anti-HIV drug break down wall between HIV-positive and HIV-negative men?
Darrell provided his perspective to CBC News on what factors are at play in rising STI rates in Canada. You can read more here.
Darrell spoke with CBC News about the potential for PrEP to reduce HIV stigma. You can read more here.